Frankestin
3 days ago
from 9.9% to 4.9%, holding 190,006 common shares.
holds 98,311 warrants to purchase common shares. However, the exercise of these warrants is subject to a 4.99% ownership limitation ("blocker"), preventing the holder from exceeding this threshold without prior adjustment.
https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=319163389&type=HTML&symbol=BCTX&cdn=4fd3b05ac8453fea46587e9835855dd1&companyName=BriaCell+Therapeutics+Corp.&formType=SCHEDULE+13G%2FA&formDescription=%5BAmend%5D+Statement+of+acquisition+of+beneficial+ownership+by+individuals&dateFiled=2025-05-13
CVI Investments, Inc., managed by Heights Capital Management, Inc., filed a Schedule 13G disclosing a passive ownership of 489,200 common shares of BriaCell Therapeutics Corp., representing approximately 8.6% of the company’s outstanding shares as of April 24, 2025.
This stake likely originates from participation in BriaCell’s public offering announced on April 24, 2025, which involved 3,066,666 units (each consisting of a common share or prefunded warrant and one warrant with a $5.25 exercise price).
https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=319127530&type=HTML&symbol=BCTX&cdn=69d3e85b7de2a0c92a3ec26bb9949c5d&companyName=BriaCell+Therapeutics+Corp.&formType=SCHEDULE+13G&formDescription=Statement+of+acquisition+of+beneficial+ownership+by+individuals&dateFiled=2025-05-01
subslover
4 weeks ago
BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™
(IMAGES BELOW) Complete resolution of lung metastasis confirmed at 4 month follow-up in hormone receptor positive (HR+) breast cancer patient
Treatment well-tolerated and patient remains on study with stable disease elsewhere
Sustained clinical response supports Bria-OTS personalized, off-the-shelf immunotherapy approach in Phase 1/2a metastatic breast cancer study
PHILADELPHIA and VANCOUVER, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, confirms the sustained complete resolution of the lung metastasis, first reported in February 2025, two months after initial treatment in the ongoing Phase 1/2 Bria-OTS study. The latest data at four months also demonstrates stable disease elsewhere.
Figure 1: Treatment with Bria-OTS monotherapy resulted in 100% resolution of tumor in the lung of the metastatic breast cancer (MBC) patient following 2 months of therapy and confirmed at 4 months of therapy1 (axial and coronal views)
https://ml.globenewswire.com/Resource/Download/19a24c7d-e793-4f57-b0df-c1605b7395dc/briacell-figure-1.png
As shown, the lesion in the patient’s right lung is undetectable after two months and confirmed resolved at 4 months. The updated images supersede those previously reported.
The patient, a 78-year-old woman with metastatic breast cancer (hormone receptor positive, HER2 negative), had failed several prior lines of therapy and received the lowest dose level in the Phase 1/2a Bria-OTS study. At enrollment on November 21, 2024, she had extensive metastases including bone, lymph node and lung involvement. Following Bria-OTS intradermal injections every 2 weeks for six weeks (4 total doses), and subsequent dosing every 3 weeks, the lung metastasis completely resolved with stable disease elsewhere. This response is now confirmed and shows the potentially promising activity of the Bria-OTS platform as monotherapy.
“Despite recent advancements with Antibody-drug-conjugates (ADCs) and immune check point inhibitors (CPIs), many patients, including those with HR+ disease, like BriaCell’s first OTS patient, have very few options,” stated Neal S. Chawla MD, Director at the Sarcoma Oncology Center, Santa Monica, Ca., and Principal Investigator for the Bria-OTS study. “We are thrilled with our initial data with single agent Bria-OTS showing rapid and strong anti-tumor activity in an HR+ patient and look forward to continuing this novel approach in patients with MBC, and other cancers.”
“This unprecedented anti-cancer response in the first patient dosed with Bria-OTS is an important milestone for us and provides early validation of BriaCell’s personalized immunotherapy approach,” stated Dr. William V. Williams, BriaCell’s President and CEO.
Bria-OTS is a personalized off-the-shelf immunotherapy, currently under investigation in a Phase 1/2a dose escalation study (ClinicalTrials.gov identifier: NCT06471673) in metastatic recurrent breast cancer. Bria-OTS represents a personalized, next generation, advancement of BriaCell’s lead candidate Bria-IMT™ which is currently in a pivotal Phase 3 study for metastatic breast cancer. The Phase 1/2a clinical trial in metastatic breast cancer is a dose escalation study initially evaluating the safety and efficacy of Bria-OTS as monotherapy and will be followed by Bria-OTS in combination with an immune checkpoint inhibitor.
About BriaCell Therapeutics Corp.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements,
Invest-in-America
4 months ago
BCTX: Could you imagine where the PRICE of this stock would be right now, if this Firm had PR'd legitimate STATISTICS to the effect that 75% of the 'Investigational Drug Group' enjoyed 100% remission of their metastasized LUNG CANCERS --- when compared to the 'Placebo Group", & all other 'Control Groups' & 'Standard of Care Groups'??? (And moreover, this HOAX Company did NOT even entertain ANY 'Control Groups', nor 'Standard of Care Groups', AT ALL!!! Their only experimental 'competition', as it were, was a useless 'PLACEBO GROUP'!!! I myself KNOW this stuff, Peeps!!! Anyone who got suckered by the conspicuous NONSENSE within BCTX's PR today, is patently-STUPID --- even when compared to all universal, 'Standards of Stupidity!!!)
"Tell-it-like-it-is, Oh Great Invest-in-America, Dude!!! You're doing GOD's work, Homeboy!!!"
/////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
axelvento
4 months ago
huge news-Treatment with Bria-OTS™ monotherapy resulted in 100% resolution of tumor in the lung of the MBC patient following 4 injection cycles
This 78-year-old woman with metastatic breast cancer (hormone receptor positive, HER2 negative) had failed several prior lines of therapy and received the lowest dose level in the Phase 1/2a Bria-OTS™ study. At enrollment on Nov 21, 2024, she had extensive metastases including multiple bone, lymph node and lung metastases. Following 4 injections with Bria-OTS™ every 2 weeks, the lung metastasis completely resolved, and she had stable disease elsewhere.
https://feeds.issuerdirect.com/news-release.html?newsid=7417246418288908